The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay
Abstract
BACKGROUND: Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely variable, ranging from 29% to 100% in earlier clinical studies. METHODS: Studies performed to date have analyzed performance using per-patient calculations, limiting their ability to measure the impact of clinical variables that change over time, such as receipt of preventive antifungal therapy. In our study, performance of the test was calculated in per-patient and per-test analyses in a large cohort of patients at high risk for IA from 2 North American centers. A total of 272 serum samples obtained from 46 patients with IA and 3005 serum samples obtained from 269 control patients were analyzed using multiple index cutoff values to define positivity. RESULTS: Per-patient calculations yielded sensitivities of 43% and 70% using index cutoff values of 1.5 and 0.5, respectively; specificity decreased from 93% with use of the 1.5 index cutoff to 70% with use of the 0.5 index cutoff. Per-test calculations yielded sensitivities of 31% and 59% and specificities of 99% and 92% using index cutoff values of 1.5 and 0.5, respectively. Receipt of mold-active antifungal drugs on the day of testing decreased sensitivity; samples obtained from patients not receiving prophylactic or empirical antifungal drugs yielded a sensitivity of 89% and a specificity of 92% (with use of an index cutoff value of 0.5). CONCLUSIONS: These findings have direct implications for preventive strategies, because the diagnostic utility of the antigen assay is compromised during receipt of prophylactic or empirical antifungal therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Maertens, J., Verhaegen, J., Lagrou, K., Van Eldere, J., & Boogaerts, M. (2001) · Blood · doi:10.1182/blood.v97.6.1604 · Cited by 513
Marr, K. A., Balajee, S. A., McLaughlin, L., Tabouret, M., Bentsen, C., & Walsh, T. J. (2004) · The Journal of Infectious Diseases · doi:10.1086/422009 · Cited by 483
Self-citationDetection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Mennink-Kersten, M. A., Donnelly, J. P., & Verweij, P. E. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01045-x · Cited by 482
Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B., & Corey, L. (2004) · Blood · doi:10.1182/blood-2003-08-2644 · Cited by 442
Self-citationAspergillus Galactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients
Herbrecht, R., Letscher-Bru, V., Oprea, C., Lioure, B., Waller, J., Campos, F., Villard, O., Liu, K.-L., Natarajan-Amé, S., Lutz, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.004 · Cited by 392
Stynen, D., Goris, A., Sarfati, J., & Latgé, J. P. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.2.497-500.1995 · Cited by 330
Musher, B., Fredricks, D., Leisenring, W., Balajee, S. A., Smith, C., & Marr, K. A. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.12.5517-5522.2004 · Cited by 283
Self-citationKawazu, M., Kanda, Y., Nannya, Y., Aoki, K., Kurokawa, M., Chiba, S., Motokura, T., Hirai, H., & Ogawa, S. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2733-2741.2004 · Cited by 280
Rat monoclonal antibodies against Aspergillus galactomannan
Stynen, D., Sarfati, J., Goris, A., Prévost, M. C., Lesourd, M., Kamphuis, H., Darras, V, & Latgé, J. P. (1992) · Infection and Immunity · doi:10.1128/iai.60.6.2237-2245.1992 · Cited by 267
Petraitis, V., Petraitiene, R., Sarafandi, A. A., Kelaher, A. M., Lyman, C. A., Casler, H. E., Sein, T., Groll, A. H., Bacher, J., Avila, N. A., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/375420 · Cited by 233
Becker, M. J., Lugtenburg, E. J., Cornelissen, J. J., Van Der Schee, C., Hoogsteden, H. C., & De Marie, S. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04308.x · Cited by 217
Francis, P., Lee, J. W., Hoffman, A., Peter, J., Francesconi, A., Bacher, J., Shelhamer, J., Pizzo, P. A., & Walsh, T. J. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.2.356 · Cited by 185
Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.12-23.2002 · Cited by 182
Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.857-869.2001 · Cited by 179
Boutboul, F., Alberti, C., Leblanc, T., Sulahian, A., Gluckman, E., Derouin, F., & Ribaud, P. (2002) · Clinical Infectious Diseases · doi:10.1086/339324 · Cited by 179
Maertens, J., Theunissen, K., Verbeken, E., Lagrou, K., Verhaegen, J., Boogaerts, M., & Eldere, J. V. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05140.x · Cited by 169
TESTING FOR TREATMENT DIFFERENCES WITH DROPOUTS PRESENT IN CLINICAL TRIALS - A COMPOSITE APPROACH
Shih, W. J., & Quan, H. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970615)16:11<1263::aid-sim550>3.0.co;2-m · Cited by 93
Becker, M. J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg367 · Cited by 48
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Donnelly, J. P., Chen, S. C., Kauffman, C. A., Steinbach, W. J., Baddley, J. W., Verweij, P. E., Clancy, C. J., Wingard, J. R., Lockhart, S. R., Groll, A. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1008 · Cited by 2,917
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Pulmonary aspergillosis: a clinical review
Kousha, M., Tadi, R., & Soubani, A. O. (2011) · European Respiratory Review · doi:10.1183/09059180.00001011 · Cited by 752
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq147 · Cited by 704
Metadata
- Authors
- Marr, K. A., Laverdiere, M., Gugel, A., & Leisenring, W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 40
- Issue
- 12
- Pages
- 1762-1769
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2151082945
- Cited by
- 471
- References
- 20
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.